Get the Stockscreener App
11.94
0.50%
-0.06
After Hours:
11.93
-0.010
-0.08%
Bridgebio Oncology Therapeutics Inc stock is traded at $11.94, with a volume of 66,681.
It is down -0.50% in the last 24 hours and up +3.11% over the past month.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
See More
Previous Close:
$12.00
Open:
$12.05
24h Volume:
66,681
Relative Volume:
0.30
Market Cap:
$945.61M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.94%
1M Performance:
+3.11%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.79
$12.35
1-Week Range:
$10.82
$12.35
52-Week Range:
$8.70
$13.18
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Name
Bridgebio Oncology Therapeutics Inc
Sector
Industry
Phone
857 702 0377
Address
C/O CORMORANT ASSET MANAGEMENT, LP, BOSTON
Compare BBOT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
11.94 | 950.36M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| Sep-15-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Latest News
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) - The Manila Times
BridgeBio Oncology Therapeutics, Inc. (BBOT) stock price, news, quote and history - Yahoo! Finance UK
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducin - The Manila Times
Preclinical Data Presented at the 2025 AACR-NCI-EORTC - GlobeNewswire
BBOT presents preclinical data on KRAS inhibitor BBO-11818 - BioWorld MedTech
BridgeBio Oncology announces new preclinical data on BBO-11818 study - TipRanks
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
BBOT Presents Preclinical Data Demonstrating Potential of - GlobeNewswire
BridgeBio Oncology (NASDAQ: BBOT) reports BBO-11818 panKRAS data; Phase 1, H2 2026 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), OnKure Therapeutics (OKUR) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
BridgeBio Oncology Therapeutics, Inc. (BBOT) - Yahoo! Finance Canada
BridgeBio affiliate reports 784,720 BBOT shares via services - Stock Titan
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM) - The Globe and Mail
Bbot announces poster presentations at the 2025 AACR-NCI-EORTC International Conference - MarketScreener
Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference - TradingView
BBOT Announces Poster Presentations at the 2025 - GlobeNewswire
2 Poster Presentations: BBOT to Present KRAS-targeted preclinical data at AACR-NCI-EORTC Oct 2025 - Stock Titan
BridgeBio Oncology Therapeutics, Inc. (BBOT) environment, social and governance (ESG) ratings - Yahoo
BridgeBio Oncology Therapeutics Rings the Closing Bell - Nasdaq
BridgeBio Oncology Therapeutics Inc (NASDAQ: BBOT) Is Up 8.01% – Is It Capable Of A Rally? - stocksregister.com
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform (BBOT:NASDAQ) - Seeking Alpha
Leerink Partners Initiates BridgeBio Oncology Therapeutics at Outperform - MarketScreener
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating - Investing.com India
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com UK
HC Wainwright Initiates BridgeBio Oncology Therapeutics at Buy With $27 Price Target - MarketScreener
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com India
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer By Investing.com - Investing.com Nigeria
Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target - MarketScreener
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - MSN
BridgeBio Oncology Therapeutics, Inc. (BBOT) company profile and facts - Yahoo! Finance UK
BridgeBio Oncology Therapeutics shares rise 4.57% after-hours after announcing participation in September investor conferences. - AInvest
BBOT to Participate in Upcoming September Investor Healthcare Conferences - The Manila Times
BBOT to Participate in Upcoming September Investor Healthcare Conferences - GlobeNewswire Inc.
BridgeBio's Strategy To Unleash The Full Potential Of RASDrugging The Undruggable - RTTNews
BridgeBio Oncology Therapeutics shares rise 11.34% premarket after Wedbush initiates coverage. - AInvest
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely - Yahoo Finance
We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth - simplywall.st
BridgeBio Oncology Therapeutics shares rise 1.17% intraday after Piper Sandler initiates coverage. - AInvest
Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target - MarketScreener
BBOT Forecast — Price Target — Prediction for 2026 - TradingView
BridgeBio Oncology initiated with an Overweight at Piper Sandler - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Price, News, Quote & History - Yahoo! Finance Canada
What is the current Price Target and Forecast for BridgeBio Oncology Therapeutics, Inc (BBOT) - Zacks Investment Research
Bridgebio Oncology Therapeutics, Inc. shares rise 2.12% intraday after Helix Acquisition Corp. II retains more than 60% of trust account. - AInvest
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating - Investing.com
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Financials Data
There is no financial data for Bridgebio Oncology Therapeutics Inc (BBOT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):